Fulminant hepatic failure (FHF) is a devastating clinical syndrome with extremely poor prognosis and high mortality. Therefore, better treatment is urgently needed. Polydatin (PD), a traditional anti-inflammatory drug, has been described to protect against liver injury induced by certain hepatotoxins. The present study investigated the protective effect of PD against lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced FHF in mice and the underlying mechanism. Mice were pretreated with an increasing dose of PD (10, 30, and 100 mg/kg), following LPS/D-GalN challenge. The liver injury was assessed biochemically and histologically. We found that PD exerted a protective effect on LPS/D-GalN-induced FHF as evidenced by reducing sera alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, diminishing liver histopathological injury, and lowering mortality in a dose-dependent manner. In addition, pretreatment mice with PD dose-dependently suppressed tumor necrosis factor-α (TNF-α) production, myeloperoxidase (MPO) activity, intercellular adhesion molecule-1 (ICAM-1) and endothelial cell adhesion molecule-1 (ECAM-1) expression, caspase-3 activation, and transcription factor nuclear factor-kappa B(NF-kB) activity induced by LPS. These results suggested that PD could effectively protect from LPS/D-GalN-induced FHF and the protective effect afforded by PD probably contributed to reduce TNF-α production via inhibiting NF-kB activation.
AntoniadesCGBerryPAWendonJAVerganiD. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol2008; 49:845–61.
2.
PossamaiLAAntoniadesCGAnsteeQM. Role of monocytes and macrophages in experimental and human acute liver failure. World J Gastroenterol2010; 16:1811–9.
3.
AlamSAzamGMustafaG. Natural course of fulminant hepatic failure: The scenario in Bangladesh and the differences from the west. Saudi J Gastroenterol2009; 15:229–33.
4.
KimSHKimYSKangSSBaeKHungTMLeeSM. Anti-apoptotic and hepatoprotective effects of gomisin A on fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice. J Pharmacol Sci2008; 106:225–33.
5.
RolandoNWadeJDavalosMWendonJPhilpott-HowardJWilliamsR. The systemic inflammatory response syndrome in acute liver failure. Hepatology2000; 32:734–9.
6.
GongXLuoFLZhangLLiHZWuMJLiXH. Tetrandrine attenuates lipopolysaccharide-inducedfulminant hepatic failure in D-galactosamine sensitized mice. Int Immunopharmacol2010; 10:357–63.
7.
PryhuberGSHuyckHLRoperJM. Acute tumor necrosis factor-alpha-induced liver injury in the absence of tumor necrosis factor receptor-associated factor 1 gene expression. Am J Pathol2005; 166:1637–45.
8.
SchwabeRFBrennerDA. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: Role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol2006; 290:G583–9.
9.
XiaoKXuanLXuYBaiDZhongD. Constituents from Polygonum cuspidatum. Chem Pharm Bull (Tokyo)2002; 50:605–8.
10.
ZhangLPMaHJBuHM. Polydatin attenuates ischemia/reperfusion-induced apoptosis in myocardium of the rat. Sheng Li Xue Bao2009; 61:367–72.
11.
DengYHAlexDHuangHQ. Inhibition of TNF-alpha-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4′l-trimethoxystilbene. Phytother Res2011; 25:451–7.
12.
HuangHXZhaoQJinCH. Effect of polydatin on lipopolysaccharide-induced leucocyte chemotaxis. Di Yi Jun Yi Da Xue Xue Bao2003; 23:1253–6.
13.
HuangZSWangZWLiuMPZhongSQLiQMRongXL. Protective effects of polydatin against CC1 (4)-induced injury to primarily cultured rat hepatocytes. World J Gastroenterol1999; 5:41–4.
14.
ZhangHYuCHJiangYP. Protective Effects of polydatin from Polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice. PLoS One2012;7:e46574.
15.
WanJYGongXZhangLLiHZZhouYFZhouQX. Protective effect of baicalin against lipopolysaccharide/D-galactosamine-induced liver injury in mice by up-regulation of heme oxygenase-1. Eur J Pharmacol2008; 587:302–8.
16.
EndoYShibazakiMYamaguchiK. Enhancement by galactosamine of lipopolysaccharide(LPS)-induced tumour necrosis factor production and lethality: Its suppression by LPS pretreatment. Br J Pharmacol1999; 128:5–12.
GalanosCFreudenbergMAReutterW. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA1979; 76:5939–43.
19.
FotioALOllerosMLVesinD. In vitro inhibition of lipopolysaccharide and mycobacterium bovis bacillus Calmette Guerin-induced inflammatory cytokines and in vivo protection from D-galactosamine/LPS -mediated liver injury by the medicinal plant Sclerocarya birrea. Int J Immunopathol Pharmacol2010; 23:61–72.
20.
KinoshitaSInoueYNakamaSIchibaTAniyaY. Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from Okinawa Island and its tannin corilagin. Phytomedicine2007; 14:755–62.
21.
OllerosMLVesinDFotioAL. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol2010; 53:1059–68.
22.
Koike-KiriyamaNAdachiYIwasakiM. High mortality rate of (NZW x BXSB) F1 mice induced by administration of lipopolysaccharide attributes to high production of tumour necrosis factor-alpha by increased numbers of dendritic cells. Clin Exp Immunol2008; 154:285–93.
23.
WangHLiY. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol2006; 534:194–201.
HoshinoKTakeuchiOKawaiT. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol1999; 162:3749–52.
26.
SalamoneGTrevaniAMartinezD. Analysis of the mechanisms involved in the stimulation of neutrophil apoptosis by tumour necrosis factor-alpha. Immunology2004; 113:355–62.
27.
ChengYJYangBCLiuMY. Lead increases lipopolysaccharide-induced liver-injury through tumor necrosis factor-alpha overexpression by monocytes/macrophages: Role of protein kinase C and P42/44 mitogen-activated protein kinase. Environ Health Perspect2006; 114:507–13.
28.
ZhangJTanYYaoFZhangQ. Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-alpha and SREBP-1c. Mol Med Report2012; 6:815–20.
29.
OhiraHAbeKYokokawaJ. Adhesion molecules and CXC chemokines in endotoxin-induced liver injury. Fukushima J Med Sci2003; 49:1–13.
30.
SteeberDATedderTF. Adhesion molecule cascades direct lymphocyte recirculation and leukocyte migration during inflammation. Immunol Res2000; 22:299–317.
31.
SumaginRSareliusIH. TNF-alpha activation of arterioles and venules alters distribution and levels of ICAM-1 and affects leukocyte-endothelial cell interactions. Am J Physiol Heart Circ Physiol2006; 291:H2116–25.
32.
KalogerisTJLarouxFSCockrellA. Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol1999; 276:C856–64.
33.
ReadMANeishASLuscinskasFWPalombellaVJManiatisTCollinsT. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity1995; 2:493–506.
34.
BreckwoldtMOChenJWStangenbergL. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci USA2008; 105:18584–9.
35.
SeoJYYuJHLimJWMukaidaNKimH. Nitric oxide-induced IL-8 expression is mediated by NF-kappaB and AP-1 in gastric epithelial AGS cells. J Physiol Pharmacol2009; 60(S)7:101–6.
36.
TapalagaDTiegsGAngermullerS. NFkappaB and caspase-3 activity in apoptotic hepatocytes of galactosamine-sensitized mice treated with TNFalpha. J Histochem Cytochem2002; 50:1599–609.
37.
WullaertAHeyninckKBeyaertR. Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol2006; 72:1090–101.
38.
Van BerloDKnaapenAMvan SchootenFJSchinsRPAlbrechtC. NF-kappaB dependent and independent mechanisms of quartz-induced proinflammatory activation of lung epithelial cells. Part Fibre Toxicol2010; 7:13.
39.
SasakiMJordanPWelbourneT. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol2005; 5:3.
